Schrödinger, Inc. (SDGR) stock analysis

Healthcare · Health Information Services

From the 10-K filed 2026-02-25

Business type: Asset play

How it makes money

It generates revenue by licensing physics-based software to the top 20 pharmaceutical companies, who accounted for $73.7 million, or 37%, of software revenue in 2025.

It earns through two segments: software licensing and drug discovery. Software revenue is concentrated in a cohort of 27 commercial customers with annual contract values over $1.0 million, averaging $3.9 million each.

The drug discovery segment provides a separate profit stream from milestones and royalties on 20 active collaborative programs with partners like Novartis and BMS, as well as cash windfalls from selling equity in co-founded biotech firms.

What protects it: the moat

It retains commercial customers with a 96% gross dollar retention rate, anchored by physics-based algorithms that simulate molecule binding without requiring training data.

The platform relies on first-principles physics rather than traditional machine learning, which management claims allows it to evaluate billions of molecules that AI cannot extrapolate to.

This scientific differentiation is evidenced by its 96% gross dollar retention and the fact that its Glide software is described as one of the most cited papers in medicinal chemistry history, creating a high barrier for displacement.

What could damage it

Clinical setbacks, such as the patient deaths that prompted the discontinuation of the SGR-2921 program in 2025, can permanently impair internal pipeline value.

The company's long-term earnings potential is vulnerable to the high failure rates of drug discovery. If internal candidates fail to prove safety—as seen when the SGR-2921 program was halted due to two emergent patient deaths—the company loses both its capital investment and potential future revenue from milestones and royalties.

About Schrödinger, Inc.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Other companies in Health Information Services